KalVista Pharmaceuticals, Inc. (KALV)

Bally's Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Net Income	-183.44	-126.64	-92.91	-82.34	-46.24
Depreciation & Amortization	0.94	0.82	0.72	0.56	0.54
Loss (Gain) From Sale of Investments	-1.55	-1.23	1.13	3.15	0.53
Stock-Based Compensation	12.29	21.92	9.92	11.09	7.12
Other Operating Activities	3.82	0.75	-1.53	1.73	-0.46
Change in Accounts Payable	-4.97	4.32	1.11	1.69	0.15
Change in Unearned Revenue	10.56	-	-	-	-
Change in Other Net Operating Assets	9.45	10.85	6.31	-14.01	8.2
Operating Cash Flow	-152.91	-89.23	-75.26	-78.13	-30.17
Capital Expenditures	-0.43	-0.04	-1.2	-0.93	-0.08
Sale (Purchase) of Intangibles	-0.5	-0.4	-	-	-
Investment in Securities	91.95	-84.28	42.61	58.79	-147.57
Investing Cash Flow	91.02	-84.72	41.42	57.86	-147.65
Issuance of Common Stock	61.69	97.59	57.03	1.58	212.12
Other Financing Activities	98.04	53.12	1.09	-	-
Financing Cash Flow	159.73	150.71	58.12	1.58	212.12
Foreign Exchange Rate Adjustments	2.64	-1.21	1.24	-1.17	0.51
Net Cash Flow	100.48	-24.45	25.51	-19.86	34.8
Free Cash Flow	-153.34	-89.27	-76.46	-79.07	-30.25
Free Cash Flow Per Share	-3.09	-2.43	-2.74	-3.23	-1.58
Levered Free Cash Flow	-92.91	-50.27	-52.01	-60.09	-21.2
Unlevered Free Cash Flow	-89.29	-50.27	-52.01	-60.09	-21.2
Change in Net Working Capital	-15.9	-15.22	-7.84	10.42	-7.43

Updated Jul 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q